Lo Joan C, Hui Rita L, Grimsrud Christopher D, Chandra Malini, Neugebauer Romain S, Gonzalez Joel R, Budayr Amer, Lau Gene, Ettinger Bruce
Division of Research, Kaiser Permanente Northern California, USA; Department of Medicine, Kaiser Permanente Oakland Medical Center, USA.
Pharmacy Outcomes Research Group, Kaiser Permanente California, USA.
Bone. 2016 Apr;85:142-7. doi: 10.1016/j.bone.2016.01.002. Epub 2016 Jan 6.
Several epidemiologic studies suggest that compared to white women, Asians have a greater propensity to suffer an atypical femur fracture (AFF) while taking bisphosphonate therapy. This study examines the relative risk of AFF following bisphosphonate initiation for Asian compared to white women.
Using data from a large integrated northern California healthcare delivery system, we examined diaphyseal femur fracture outcomes among women age≥50years old who initiated oral bisphosphonate therapy during 2002-2007. An AFF was defined by the 2013 American Society of Bone and Mineral Research Task Force criteria. The risk of radiographically-confirmed AFF was examined for Asian compared to white women, adjusting for differences in bisphosphonate exposure and other potential risk factors.
Among 48,390 women (65.3% white, 17.1% Asian) who newly initiated bisphosphonate therapy and were followed for a median of 7.7years, 68 women experienced an AFF. The rate of AFF was 18.7 per 100,000 person-years overall and eight-fold higher among Asian compared to white women (64.2 versus 7.6 per 100,000 person-years). Asians were also more likely to have longer bisphosphonate treatment duration compared to whites (median 3.8 versus 2.7years). The age-adjusted relative hazard for AFF was 8.5 (95% confidence interval 4.9-14.9) comparing Asian to white women, and was only modestly reduced to 6.6 (3.7-11.5) after adjusting for bisphosphonate duration and current use.
Our study confirms marked racial disparity in AFF risk that should be further investigated, particularly the mechanisms accounting for this difference. These findings also underscore the need to further examine the association of bisphosphonate duration and AFF in women of Asian race, as well as differential risk across Asian subgroups. In the interim, counseling of Asian women about osteoporosis drug continuation should include consideration of their potentially higher AFF risk.
多项流行病学研究表明,与白人女性相比,亚洲女性在接受双膦酸盐治疗时发生非典型股骨骨折(AFF)的倾向更大。本研究旨在探讨与白人女性相比,亚洲女性开始使用双膦酸盐后发生AFF的相对风险。
利用加利福尼亚州北部一个大型综合医疗保健系统的数据,我们研究了2002年至2007年期间开始口服双膦酸盐治疗的50岁及以上女性的股骨干骨折结局。AFF根据2013年美国骨与矿物质研究学会工作组标准定义。比较亚洲女性与白人女性经影像学证实的AFF风险,并对双膦酸盐暴露差异和其他潜在风险因素进行调整。
在48390名新开始双膦酸盐治疗且中位随访7.7年的女性中(65.3%为白人,17.1%为亚洲人),68名女性发生了AFF。AFF总体发生率为每10万人年18.7例,亚洲女性的发生率是白人女性的8倍(每10万人年64.2例对7.6例)。与白人相比,亚洲女性使用双膦酸盐的治疗时间也更长(中位时间分别为3.8年和2.7年)。亚洲女性与白人女性AFF的年龄调整相对风险为8.5(95%置信区间4.9-14.9),在调整双膦酸盐使用时间和当前使用情况后,仅适度降至6.6(3.7-11.5)。
我们的研究证实了AFF风险存在明显的种族差异,应进一步研究,特别是导致这种差异的机制。这些发现还强调,需要进一步研究亚洲女性双膦酸盐使用时间与AFF的关联,以及亚洲亚组之间的不同风险。在此期间,对亚洲女性进行骨质疏松药物持续使用的咨询时,应考虑到她们可能更高的AFF风险。